ArticlePloS one2011
Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer.Oncogene · 2022Article
- Radiographic markers of breast cancer brain metastases: relation to clinical characteristics and postoperative outcome.Acta neurochirurgica · 2022Article
- Article
- Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival.BMC medical genomics · 2020Article
- LRIG1 gene copy number analysis by ddPCR and correlations to clinical factors in breast cancer.BMC cancer · 2020Article
- Centromere 17 copy number gain reflects chromosomal instability in breast cancer.Scientific reports · 2019Article
- Molecular subtyping of tumors from patients with familial glioma.Neuro-oncology · 2018Article
- Feasibility of analyzing DNA copy number variation in breast cancer tumor specimens from 1950 to 2010: how old is too old?Cancer causes & control : CCC · 2018Article
- Lunatic Fringe and p53 Cooperatively Suppress Mesenchymal Stem-Like Breast Cancer.Neoplasia (New York, N.Y.) · 2017Article
- Tumor LDH-A expression and serum LDH status are two metabolic predictors for triple negative breast cancer brain metastasis.Scientific reports · 2017Article
- Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- DNA copy number profiling in microsatellite-stable and microsatellite-unstable hereditary non-polyposis colorectal cancers by targeted CNV array.Functional & integrative genomics · 2017Article
- Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer.The American journal of pathology · 2016Article
- Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis.BMC cancer · 2015Article
- Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.PloS one · 2015Article
- Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.The Lancet. Oncology · 2014Review
- Bayesian hierarchical structured variable selection methods with application to MIP studies in breast cancer.Journal of the Royal Statistical Society. Series C, Applied statistics · 2014Article
- Loss of LRIG1 locus increases risk of early and late relapse of stage I/II breast cancer.Cancer research · 2014Article
- Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
A number of studies of copy number imbalances (CNIs) in breast tumors support associations between individual CNIs and patient outcomes. However, no pattern or signature of CNIs has emerged for clinical use. We determined copy number (CN) gains and losses using high-density molecular inversion probe (MIP) arrays for 971 stage I/II breast tumors and applied a boosting strategy to fit hazards models for CN and recurrence, treating chromosomal segments in a dose-specific fashion (-1 [loss], 0 [no change] and +1 [gain]). The concordance index (C-Index) was used to compare prognostic accuracy between a training (n = 728) and test (n = 243) set and across models. Twelve novel prognostic CNIs were identified: losses at 1p12, 12q13.13, 13q12.3, 22q11, and Xp21, and gains at 2p11.1, 3q13.12, 10p11.21, 10q23.1, 11p15, 14q13.2-q13.3, and 17q21.33. In addition, seven CNIs previously implicated as prognostic markers were selected: losses at 8p22 and 16p11.2 and gains at 10p13, 11q13.5, 12p13, 20q13, and Xq28. For all breast cancers combined, the final full model including 19 CNIs, clinical covariates, and tumor marker-approximated subtypes (estrogen receptor [ER], progesterone receptor, ERBB2 amplification, and Ki67) significantly outperformed a model containing only clinical covariates and tumor subtypes (C-Index(full model), train[test] = 0.72[0.71] ± 0.02 vs. C-Index(clinical + subtype model), train[test] = 0.62[0.62] ± 0.02; p<10(-6)). In addition, the full model containing 19 CNIs significantly improved prognostication separately for ER-, HER2+, luminal B, and triple negative tumors over clinical variables alone. In summary, we show that a set of 19 CNIs discriminates risk of recurrence among early-stage breast tumors, independent of ER status. Further, our data suggest the presence of specific CNIs that promote and, in some cases, limit tumor spread.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.